Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-54175446 in MDD with Inflammation
NCT04116606Phase 2Unknown
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Sep 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Active JNJ-54175446 with Matching placebo (2 arms). Primary endpoint: Montgomery Asberg Depression Rating Scale Total Score at 8 weeks. Status: unknown.
02
Drugs
JNJ-54175446
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04116606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116606.